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Abstract
FHL1 mutations have been associated with various disorders that include reducing body myopathy 
(RBM), Emery-Dreifuss–like muscular dystrophy, isolated hypertrophic cardiomyopathy, and 
some overlapping conditions. We report a detailed histochemical, immunohistochemical, electron 
microscopic, and immunoelectron microscopic analyses of muscle biopsies from 18 patients 
carrying mutations in FHL1: 14 RBM patients (Group 1), 3 Emery-Dreifuss muscular dystrophy 
patients (Group 2), and 1 patient with hypertrophic cardiomyopathy and muscular hypertrophy 
(Group 2). Group 1 muscle biopsies consistently showed RBs associated with cytoplasmic bodies. 
The RBs showed prominent FHL1 immunoreactivity whereas desmin, αB-crystallin, and myotilin 
immunoreactivity surrounded RBs. By electron microscopy, RBs were composed of electron-
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dense tubulofilamentous material that seemed to spread progressively between the myofibrils and 
around myonuclei. By immunoelectron microscopy, FHL1 protein was found exclusively inside 
RBs. Group 2 biopsies showed mild dystrophic abnormalities without RBs; only minor 
nonspecific myofibrillar abnormalities were observed under electron microscopy. Molecular 
analysis revealed missense mutations in the second FHL1 LIM domain in Group 1 patients and 
ins/del or missense mutations within the fourth FHL1 LIM domain in Group 2 patients. Our 
findings expand the morphologic features of RBM, clearly demonstrate the localization of FHL1 
in RBs, and further illustrate major morphologic differences among different FHL1-related 
myopathies.
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INTRODUCTION
The FHL1 protein isoforms FHL1A, FHL1B, and FHL1C are encoded by alternative 
splicing of the FHL1 gene on Xq26 chromosome (1). They contain LIM domains, highly 
conserved sequences constituted by cysteine-rich double zinc-finger motifs that mediate 
protein binding (2). FHL1A (generally named FHL1) is a 32-kd protein composed of 4.5 
LIM domains that is highly expressed in skeletal and cardiac muscle (3). In skeletal muscle, 
FHL1 localizes to the I-band and M-line of the sarcomere, the sarcolemma, and the nucleus 
(4). FHL1B (SLIMMER/KyoT3, 36 kd) and FHL1C (KyoT2, 22 kd) contain different C-
terminal domains and (because of alternative splicing) 3.5 and 2.5 LIM domains, 
respectively. They are expressed in skeletal and cardiac muscle to a lesser extent compared 
with FHL1A (1, 5–7).
Mutations in FHL1 (OMIM 300163) have been as sociated with different disorders, 
including reducing body myopathy (RBM), X-linked–dominant scapuloperoneal myopathy, 
X-linked myopathy with postural muscle atrophy (XMPMA), rigid spine syndrome, Emery-
Dreifuss muscular dystrophy (EDMD), isolated hypertrophic cardiomyopathy (HCM), and 
some overlapping conditions (1, 8). FHL1-related disorders may be divided into 2 main 
subgroups based on the muscle pathology. The first is characterized by the presence of RBs 
in muscle fibers and includes RBM, X-linked–dominant scapuloperoneal myopathy, and 
rigid spine syndrome. The presence of RBs as a constant morphologic feature suggests that 
these conditions may be considered as a spectrum of 1 unique entity that is best subsumed 
under “RBM.” The second group does not exhibit RBs in muscle biopsies and includes 
patients with EDMD, XMPMA, and the recently described FHL1-related isolated HCM (1, 
8). Exceptions to this classification seem to exist after the recent identification of RBs in 
muscle biopsies of 2 brothers with late-onset XMPMA (9).
Reducing bodies were first described more than 35 years ago as cytoplasmic inclusions that 
reduce nitro-blue tetrazolium (NBT), thus staining strongly in menadione-NBT reaction 
(10). Pioneer studies speculated that the reducing activity is likely caused by the presence of 
sulphydryl groups (11). Moreover, the close relationship between the myofilaments and the 
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RB granular material may indicate the possibility that the granules arise from some 
myofibrillar component (11). Recent proteomic studies have demonstrated that RBs 
correspond to protein aggregates, one of the major constituents of which is FHL1 (12); 
however, the presence of FHL1 inside RBs has never been demonstrated in human muscle 
tissue by immunoelectron microscopy (IEM).
Reducing body myopathy patients generally harbor missense mutations affecting conserved 
residues of FHL1 essential for the proper protein folding and stabilization of the LIM2 
domain (1). Patients without RBs harbor mutations located in the most distal exons affecting 
differently the 3 FHL1 isoforms (13–15).
To enhance understanding of the mechanisms that produce the morphologic phenotype of 
different FHL1-related myopathies, we studied 18 patients carrying a mutation in FHL1, 
including 14 RBM, 3 EDMD, and 1 patient with HCM and muscular hypertrophy patients 
using immunohistochemistry, EM, and IEM. Our results expand the pathologic spectrum of 
RBM, directly demonstrate localization of FHL1 in RBs, and further illustrate major 
morphologic differences between different clinical forms of FHL1-related myopathies.
MATERIALS AND METHODS
Patients
Eighteen patients (i.e. 14 RBM patients, 3 EDMD, and 1 patient with HCM and muscle 
hypertrophy) from 16 unrelated families were included in the present study. Patients P1, P2, 
P3, P5, P6, P7, P8, P9, P14, and P15 (n = 10) are reported herein for the first time. They 
belong to 6 unrelated families from France, Romania, and Argentina. Patients P5 and P7 are 
sons of P6 and P8, respectively. Clinical and pathologic data from patient P4 were reported 
before the causative gene for RBM was discovered (16). Data on the clinical phenotype, 
pathologic features, and genetic characterization of 7 patients, 4 with RBM (P10, P11, P12, 
P13), and 3 with an EDMD phenotype (P16, P17, and P18) have been previously described 
(13, 17).
Mutation Analysis
Patients or parents gave informed consent for the genetic analysis according to French 
legislation. Genomic DNA was extracted from blood samples by standard methods. DNAs 
were studied by direct sequencing of exons and intronexon boundaries of FHL1 gene, as 
previously described (13).
Morphologic Studies
An open muscle biopsy was performed in all patients after informed consent. Age at biopsy 
varied from 10 months to 58 years (Table). For conventional histochemical techniques, 10-
µm-thick cryostat sections were stained with hematoxylin and eosin (H&E), modified 
Gomori trichrome, periodic acid-Schiff technique, Oil red O, reduced nicotinamide adenine 
dinucleotide dehydrogenase–tetrazolium reductase, succinic dehydrogenase (SDH), 
cytochrome oxidase (COX), and adenosine triphosphatase (ATPase) preincubated at pH 9.4, 
4.63, and 4.35. The presence of RBs was assessed in muscle sections processed for the 
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menadione–nitro blue tetrazolium with or without α-glycerophosphate. Digital photographs 
of each biopsy were obtained with a Zeiss AxioCam HRc linked to a Zeiss Axioplan Bright 
Field Microscope and processed with the Axio Vision 4.4 software (Zeiss, Germany).
Immunohistochemistry and Double Immunofluorescence
Frozen muscle samples for immunohistochemical and immunofluorescence analyses were 
available only for 1 patient with RBM (P1) and for 3 patients from Group 2 (P16, P17, and 
P18). Frozen muscle was not available for the other patients.
Immunohistochemistry with antibodies to desmin (D33, 1:1000, Dako-Desmin; 
DakoCytomation, Glostrup, Denmark), αB-crystallin (NCL-ABCrys-512, 1:300; 
Novocastra, Newcastle, UK), and myotilin (NCL-Myotilin, 1:50; Novocastra) was 
performed on 8-µm-thick cryosections using an immunoperoxidase-automated procedure 
(Ventana, Illkirch, France). Subsequently, sections were incubated with an appropriate 
conjugated secondary antibody for 1 hour, and the sections were slightly counterstained with 
H&E.
For double labeling immunofluorescence staining, 6-µm-thick sections were fixed in cold 
acetone for 10 minutes. They were then incubated with anti-FHL1 antibody (ab49241, 
1:100; Abcam, Cambridge, UK) overnight at 4°C as the first antibody and subsequently with 
anti-desmin (D33, 1:1000) as the second antibody. Subsequently, sections were incubated 
with appropriate conjugated secondary antibodies for 1 hour. A set of control slides was 
prepared, with omission of the primary antibodies.
Electron Microscopy
Detailed electron microscopy analysis was performed on samples from the entire cohort. 
Small muscle specimens were fixed in glutaraldehyde (2.5%, pH 7.4), postfixed with 2% 
OsO4, dehydrated, and embedded in resin (EMBed-812; Electron Microscopy Sciences, 
Hatfield, PA). Ultrathin sections from at least 3 small blocks from each patient were stained 
with uranyl acetate and lead citrate. The grids were observed using a Philips CM120 
electron microscope (80 kV; Philips Electronics NV, Eindhoven, The Netherlands) and were 
photodocumented using a Morada camera (Soft Imaging System, France).
Immunoelectron Microscopy
Immunoelectron microscopy was performed in specimens from 14 patients (P1, P3, P4, P5, 
P6, P7, P8, P9, P10, P11, P12, P13, P15, and P17) and in an unrelated female subject 
presenting myalgia without muscle weakness whose biopsy did not have morphologic 
alterations either by light microscopy or EM (internal control). Muscle biopsies were fixed 
in a solution of 2% paraformaldehyde, 2.5% glutaraldehyde in 0.12 mol/L phosphate buffer. 
Small pieces were postfixed for 2 hours in 2% OsO4 in 0.12 mol/L cacodylate buffer, 
dehydrated in graded ethanol series and flat embedded in Epon. Ultrathin sections (80 nm) 
were etched with a saturated aqueous solution of sodium metaperiodate (15 minutes) before 
performing the immunogold labeling technique. Sections were incubated for 30 minutes in 
Tris-buffered saline containing 1% bovine serum albumin and 1% normal goat serum and 
then overnight in the same buffer containing the primary rabbit polyclonal antibody to FHL1 
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(1:50 dilution). After extensive washes in Tris-buffered saline, the sections were incubated 
for 3 hours with a gold-conjugated goat anti-rabbit IgG antibody (1:50 dilution; British 
BioCell, Cardiff, UK). The sections were washed in distilled water, stained with 2% uranyl 




Ten patients were female and 8 were male. According to the clinical and morphologic 
phenotype, patients were divided into 2 groups: Group 1 consisted of patients with RBM (P1 
to P14), and group 2 consisted of patients with no RBs and presented with HCM with 
muscle hypertrophy (P15) or an EDMD phenotype (P16 to P18). The age of onset varied 
from 4 months to 29 years in Group 1 and from 3 weeks to 48 years in Group 2. Clinical 
summary, laboratory features, a complete list of morphologic methods applied to muscle 
biopsies, and genetic characterization of all patients is provided in the Table.
Molecular Data
Group 1—The screening of FHL1 gene in DNA of patients newly analyzed for FHL1 
mutations resulted in identification of 6 previously described FHL1 mutations (Table; Fig. 
1). Patients P1 and P14 had 2 de novo mutations. X-linked transmission was verified in all 
relevant pedigrees. All the mutations identified in Group 1 are located in exon 5 and change 
1 of the 8 zinc-coordinating cysteine or histidine residues of the LIM2 domain (Fig. 1).
Group 2—We identified a novel mutation consisting of a nucleotide deletion c.632delA in 
exon 6 in P15 (Table). This change introduces a frame shift and a premature stop codon for 
both FHL1A and FHL1B, eventually leading to C-terminal truncated proteins lacking the 
LIM4 domain for FHL1A (p.Asp211ValfsX47) (Fig. 1), and the NSL, NES, and RBP-J 
domains for FHL1B (p.Asp211ValfsX27) (Fig. 1). The FHL1 mutations found in patients 
P16, P17, and P18 have been previously described and are located in exon 8, affecting only 
the LIM4 domain of FHL1A (Fig. 1) (12).
Histologic and Histochemical Features
Group 1—Patients P1 and P5 underwent a first biopsy in a nonaffected muscle that failed 
to show relevant alterations. The biopsy of P2 was interpreted as nonspecific. All of the 
other RBM patients showed similar morphologic abnormalities characterized by marked 
variability in fiber size, hypertrophic and atrophic-rounded fibers, and variable degrees of 
endomysial fibro–fatty tissue substitution. There were increased numbers of internal nuclei. 
The abnormalities were always focally distributed: some fascicles appeared severely 
damaged, whereas others showed only minor abnormalities.
All of the biopsies showed some enlarged nuclei; some of them showed a pale central zone 
on H&E. In all cases, scattered necrotic fibers, often undergoing phagocytosis, were 
observed. There was no perivascular or endomysial inflammation. Rimmed vacuoles were 
present only in the biopsy of patient P6 (not shown). The most striking finding was the 
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presence of RBs. These appear as bright pink cytoplasmic inclusions on H&E (Fig. 2A). 
Reducing bodies strongly reduced NBT on menadione staining with or without α-
glycerophosphate (Fig. 2B). They were devoid of oxidative activities especially with COX 
(not shown) and SDH (Fig. 2C) stains. The number and sizes of RBs varied among the 
samples; some fibers were completely replaced by them. The numbers of RBs and the 
severity of pathologic abnormalities observed in each biopsied muscle did not seem to 
correlate with the degree of disease severity or with duration of disease manifestations. In 
addition, several muscle fibers contained a mixture of amorphous and granular material that 
did not react with the menadione-NBT staining. Furthermore, cytoplasmic bodies were seen 
as collections of red granules on modified Gomori trichrome in the cytoplasm of several 
fibers. Adenosine triphosphatase staining revealed type 1 fiber predominance in all cases. In 
a single patient, there were single or multiple well-demarcated zones devoid of oxidative 
enzyme activity that closely resembled cores.
Group 2—Light microscopy findings in patient P15 showed nonspecific abnormalities 
characterized by mild variability in fiber size, some proliferation of endomysial connective 
tissue, and a few internal nuclei. No cytoplasmic inclusions or areas of myofibrillar 
disorganization were identified (not shown). The biopsies of patients P16, P17, and P18 
showed only mild dystrophic features (13).
Immunohistochemistry and Immunofluorescence
Group 1 and Group 2—Desmin, myotilin, and αB-crystallin immunoreactivities were 
absent from the areas corresponding to RBs, but they were enhanced at their periphery, as 
seen on serial sections processed for menadione-NBT and for these immunostains (Fig. 2B, 
D–F). Moreover, diffuse desmin, myotilin, and αB-crystallin overexpression was observed 
in atrophic fibers (Fig. 2D–F).
Immunofluorescence analysis of control muscle sections revealed diffuse FHL1 cytoplasmic 
expression (Fig. 3A). In contrast, a section from P1 showed that the intracytoplasmic 
inclusions corresponding to RBs were strongly immunolabeled for FHL1 (Fig. 3B). 
Interestingly, regions of the fibers in proximity to RBs and adjacent normal fibers showed 
absence of FHL1 immunoreactivity (Fig. 3B). Muscle biopsy sections from group 2 patients 
revealed less intense FHL1 immunofluorescence versus controls (Fig. 3C).
Double immunofluorescence analysis with anti-FHL1 and anti-desmin antibodies revealed 
partial colocalization of both proteins at the periphery of RBs (Fig. 3D, E), diffuse 
colocalization in atrophic fibers, and no colocalization within RBs (Fig. 3D). Moreover, 
increased FHL1 immunofluorescence was observed in perinuclear areas (Fig. 3D, F).
Electron Microscopy
Group 1—Biopsies with RBs by light microscopy showed a wide spectrum of 
ultrastructural features depending on the stage of the lesions; regional distribution of 
pathologic alterations was also confirmed. Early changes were characterized by the presence 
of highly osmiophilic granular material seeming to emanate from structures corresponding 
to the I-band and extending perpendicularly and longitudinally to the sarcomere (Fig. 4A). 
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Fine filamentous semidense material was also observed near the Z-line and extended along 
the sarcomere (Fig. 4B). Clusters of mitochondria and glycogen granules were very often 
observed adjacent to both types of material. In fibers showing more advanced lesions, the 
osmiophilic coarse tubulofilamentous granular material appeared to spread to the 
subsarcolemma and between the myofibrils, giving rise to the formation of large inclusions 
that correspond to the RBs visualized with menadione-NBT staining. Reducing bodies were 
composed of coarse tubulofilaments (Fig. 4C). Typical cytoplasmic bodies with a dense core 
and a clear halo of fine filaments were found surrounding or intermingled with the RBs (Fig. 
5A, B). In all cases, there was osmiophilic granular/tubulofilamentous material around 
myonuclei (Fig. 5C–F). Thus, myonuclei invariably appeared to be encased by RBs. In 
addition, some nuclei showed a number of abnormalities, including apoptotic changes, 
hypercondensed chromatin, prominent nucleoli, and even the presence of intranuclear 
osmiophilic granular material.
Most severely damaged fibers showed completely disrupted sarcomeric structures replaced 
by RBs, cytoplasmic bodies, filamentous material, mini–nemaline rods, autophagic 
vacuoles, remnants of filaments, lipid droplets, and clusters of enlarged mitochondria.
Several additional abnormalities were observed. The biopsy of patient P13 showed large 
numbers of fingerprint bodies in several fibers (Fig. 6A, B). Dilated sarcotubular cisternae 
were observed in 5 patients (P1, P7, P8, P9, and P10), and honeycomb structures were 
observed in the biopsy of P1 (Fig. 6C). The muscle of patient P13 showed the presence of 
intranuclear rods (Fig. 6D).
Group 2—Ultrastructural studies demonstrated only minor abnormalities, characterized by 
nonspecific irregularities of the Z-line. Neither osmiophilic granular deposits nor semidense 
filamentous material was observed in any case (not shown).
Immunoelectron Microscopy
Our protocol for immune electron microscopy in Epon-embedded muscle sections allowed 
us to develop a specific gold-labeled FHL1 staining. The IEM analysis conducted in our 
internal control and in Group 2 patients (P15 and P17) revealed the presence of gold-labeled 
FHL1 adjacent to the Z-line, I-band, and M-line, corresponding to the expected normal 
location for FHL1 in unaffected skeletal muscle (Figure, Supplemental Digital Content 1, 
http://links.lww.com/NEN/A481).
In the biopsies of all 12 Group 1 patients, we found that gold-labeled FHL1 antibody was 
strongly enriched in the electron-dense inclusion corresponding to RBs (Fig. 7A, B). 
Reducing body material surrounding nuclei was also enriched with FHL1 immunoreactivity 
(Fig. 8), and this immunoreactivity clearly corresponded to the perinuclear labeling seen by 
immunofluorescence (Fig. 3D, F). Moreover, the cytoplasmic bodies intermingled with RB 
material never stained with FHL1 antibody (Fig. 9). In the more preserved areas of the 
Supplemental digital content is available for this article. Direct URL citation appear in the printed text and is provided in the HTML 
and PDF versions of this article on the journal’s Web site (www.jneuropath.com).
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muscle biopsies, we also noticed some binding adjacent to the Z-line/I-band/M-line (not 
shown).
DISCUSSION
We have reported a detailed comparative histologic, immunohistochemical, ultrastructural, 
and IEM analysis in a large cohort of 18 patients carrying mutations in the FHL1 gene.
Patients P1 to P14 had severe RBM, and all harbored previously reported mutations located 
in the LIM2 FHL1 domain. A striking asymmetric pattern of muscle weakness and atrophy 
was present in 5 of the female RBM patients whose clinical onset was in late childhood or in 
early adulthood. Patients P5, P6, P7, and P8 are sons and mothers affected by the same 
FHL1 LIM2 domain mutation. Of interest, the 2 mothers (P6 and P8) manifested a striking 
asymmetric phenotype compared with their sons. X-linked inactivation studies were not 
performed in our patients, but variable expression of mutated X allele could result in the 
different clinical expression encountered in these 2 pedigrees. Thus, FHL1 mutation 
screening should be considered in the diagnostic workup of female patients presenting with 
progressive asymmetric muscle weakness and atrophy with onset in early adult life.
In Group 2 patients, P15 has a novel FHL1A p.Asp211ValfsX47/FHL1B 
p.Asp211ValsfX27-mutation in exon 6 associated with HCM and muscular hypertrophy. 
Patients P16, P17, and P18 have an EDMD phenotype associated with mutations modifying 
differently the 3 FHL1 isoforms, that is, with LIM4 and/or C-terminal and LIM4 domain 
alterations (13).
Our morphologic analysis allows us to confirm distinct morphologic phenotypes in the 2 
groups. Muscle biopsies from patients belonging to Group 2 showed mild dystrophic 
features but no RBs. By contrast, muscle biopsies from Group 1 patients displayed a 
consistent pathologic picture, with characteristic histologic findings of round or oval RBs, 
commonly localized at the outer edge of muscle fibers or surrounding enlarged myonuclei, 
and cytoplasmic bodies. These 2 different types of inclusions are typically found only in 
some sectors of the muscle sections (12, 17, 18). For this reason, the choice of a clinically 
affected muscle as the site for a biopsy is critical for maximizing the probability of 
encountering RBs and cytoplasmic bodies, the pathologic changes associated with RBM. 
This is the first observation of fingerprint bodies and intranuclear rods associated with RBM. 
Immunofluorescence studies in P1 confirmed the presence of increased FHL1 
immunoreactivity in RB areas and in atrophic fibers. A complete absence of FHL1 
immunostaining in nonaffected areas of the muscle biopsy was also observed. More 
interestingly, perinuclear regions of fibers containing RBs showed increased FHL1 
reactivity. This is consistent with the accumulation of mutant FHL1B and/or FHL1C nuclear 
isoforms. In contrast, group 2 patient biopsies showed a homogeneous but less intense 
sarcomeric distribution compared with that in control muscle.
It has been recently proposed that RBM can show typical features of myofibrillar myopathy 
(18). Therefore, we performed immunostaining directed against myofibrillary components. 
Desmin, αB-crystallin, and myotilin-immunoreactive material was present exclusively at the 
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periphery and constantly absent from RB. Using double immunofluorescence with FHL1 
and desmin antibodies, we demonstrated that desmin seems to form scaffold-like structures 
around RB, a feature characteristic of aggresomes, which are usually “caged” by an 
intermediate filament network (19). Taken together, our immunohistochemical and 
ultrastructural analysis indicates that the type and composition of protein aggregates in RBM 
are markedly different from those found in other myofibrillar myopathy subtypes.
Ultrastructural analysis demonstrated that the initial lesion consisted of tubulofilaments that 
emerged in the vicinity of the I-band, suggesting that the initial pathologic aggregation 
process possibly started at the site of normal FHL1 localization. In fibers with more severe 
morphologic changes, RB material invaded the entire myofiber spreading around the nuclei 
and dislocating all its components.
Our study does, however, have some limitations because there was not sufficient frozen 
material to extend our immunofluorescence studies to the entire cohort, and the observations 
of perinuclear FHL1 staining and ultrastructural evidence of RB material around myonuclei 
were only correlative. Nevertheless, we wanted to address specific questions regarding 
FHL1 contributions in RB formation and distribution by IEM. Schessl et al (17) previously 
described IEM on reembedded frozen material from an RBM patient. The electron-dense 
inclusion showed some gold-labeled FHL1 enrichment, but the muscular ultrastructure was 
not well preserved because of the freezing (17). With a different approach using Epon-
embedded muscle, we obtained a well-preserved sarcomeric structure, enabling us to address 
this issue. Indeed, FHL1 was found inside the intermyofibrillar and perinuclear RB. Our data 
strongly support the idea that LIM2-mutated FHL1 protein deposition could start and 
possibly precipitate protein aggregation. Further IEM studies aimed at identifying the 
contribution of different FHL1 isoforms in RB formation are planned.
In addition, we confirmed the expected FHL1 localization in skeletal muscle adjacent to the 
Z-line, I-band, and M-line (4).
Finally, in this study of a large cohort of FHL1-mutated patients, we were able to improve 
characterization of the pathologic spectrum associated with 2 groups of FHL1-related 
myopathies and demonstrated ex vivo the FHL1 contribution to RB formation. More studies 
are needed to dissect the pathophysiology of FHL1-related myopathies for the development 
of suitable therapeutic strategies.
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Distribution of mutations along the FHL1 gene, corresponding transcript isoforms, and their 
consequences on the 3 FHL1 protein isoforms. (Top panel) The FHL1 gene gives rise by 
alternative splicing to 3 major transcribed isoforms FHL1A, B, and C. Dark gray squares 
represent alternatively spliced exons. Translational start (ATG) and stop (TAA or TGA) 
codons are indicated for the 3 FHL1 isoforms. The FHL1 mutations identified in reducing 
body myopathy (RBM) patients are depicted in light blue (with corresponding family 
number in parentheses), in dark blue for Emery-Dreifuss muscular dystrophy (EDMD-
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phenotype) patients, and in red for the hypertrophic cardiomyopathy and muscle 
hypertrophy (HCM + MD) patient. (Bottom panel) The 3 FHL1 protein isoforms are 
represented at the top of the panel, with indication of the position of the missense mutations. 
Below are presented the putative consequences at the protein level of the missense mutation 
suppressing the FHL1A stop codon and the 3 truncating mutations.
Malfatti et al. Page 12














Light microscopy and histochemistry of muscle in reducing body myopathy. Serial 
transverse muscle sections from patient P1 muscle biopsy. (A) Reducing bodies (RBs) 
appear as bright pink cytoplasmic inclusions on H&E. (B) Reducing bodies are labeled blue 
strongly with the reducing nitro-blue tetrazolium (NBT)–menadione reaction; (C) they do 
not stain for succinic dehydrogenase (SDH). (D–F) Desmin, αB-crystallin, and myotilin are 
not found inside RBs. Scale bar = (A–F) 20 µm.
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Immunofluorescence of muscle in a control and in reducing body myopathy. (A) FHL1 
immunofluorescence in a control muscle shows localization of the protein to the sarcomere. 
(B) In a muscle section from patient P1, FHL1 immunoreactivity is absent in normal fibers 
but there is intense staining of atrophic fibers or in fibers containing reducing body (RB) 
material. (C) Patient 17 from Group 2 shows a homogeneous but less intense FHL1 pattern 
versus the control muscle. (D–F) Intracytoplasmic inclusions corresponding to RBs are 
strongly labeled with an anti-FHL1 antibody (D). Desmin immunoreactivity is found at the 
periphery of the RBs but not inside them (white stars in D–F). In particular, desmin 
accumulation seems to form a scaffolding structure around RBs (D, F). Double labeling 
immunofluorescence analysis using antibodies against FHL1 and desmin (F). There is 
increased FHL1 immunoreactivity around myonuclei (arrows in [D] and [F]). Scale bar = 
(A–F) 20 µm.
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Electron microscopy of muscle in reducing body (RB) myopathy. (A) Highly osmiophilic 
granular material seems to emanate from the I-band (indicated by arrows). (B) Fine 
filamentous semidense material is observed near the Z-line and extending along the 
sarcomere (indicated by a star). (C) RB material corresponds to coarse tubulofilaments 
(indicated by an arrow). Original magnification: (A) 14,000×; (B) 14,800×; (C) 21,500×.
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Electron microscopy of muscle in reducing body (RB) myopathy. (A, B) Typical 
cytoplasmic bodies (stars) with a dense core and a clear halo of fine filaments surround or 
are intermingled with the RBs (arrows). (C–F) Osmiophilic tubulofilamentous material 
corresponding to RBs is consistently localized around myonuclei. (F) Higher power image 
of (E). Original magnification: (A) 14,000×; (B) 21,500×; (C) 21,800×; (D) 21,000×; (E) 
32,000×; (F) 110,000×.
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Electron microscopy of muscle in reducing body myopathy. (A, B) Fingerprint bodies. (B) 
Higher magnification of (A). (C) Dilated sarcotubular cisternae. (D) Intranuclear rod. 
Original magnification: (A) 14,300×; (B) 45,000×; (C) 6,000×; (D) 14,000×.
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Immunoelectron microscopy of muscle in reducing body (RB) myopathy. (A, B) Gold-
labeled anti-FHL1 antibody label is strongly enriched in the electron-dense inclusion 
corresponding to an RB. (B) Higher magnification of (A). Original magnification: (A) 
13,700×; (B) 41,000×.
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Immunoelectron microscopy of muscle in reducing body (RB) myopathy. RB material 
surrounding nuclei is partly composed of FHL1. Original magnification: 18,300×.
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Immunoelectron microscopy of muscle in reducing body (RB) myopathy. Cytoplasmic 
bodies do not show reactivity with a gold particle–labeled FHL1 antibody, whereas RB 
material intermingled with cytoplasmic bodies (arrow) is immunoreactive with the FHL1 
antibody. Original magnification: 28,300×.
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